The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...

The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...

A recent study has uncovered key insights into the differing tumour rejection behaviours of chimeric antigen receptor T cells ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...

The FDA clears ALLO's investigational new drug application to start clinical studies on its investigational CAR T product, ALLO-329, for autoimmune diseases.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

FRIENDSHIP. DAO has officially launched as a next-generation blockchain-based platform, transforming how independent artists and their supporters collaborate within the global music ecosystem. By ...

Ocient, the leading data analytics software solutions company, today announced a collaboration with AMD to boost performance, lower costs, and maximize the efficiency of compute-intensive data and AI ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

Researchers have revolutionized cancer immunotherapy by developing a way to grow T cells in the lab that live longer and ...

Researchers from the University of Pittsburgh have developed a new way to grow T cells in the lab that enables them to live longer and better destroy cancer cells in a mouse model of melanoma compared ...